129 related articles for article (PubMed ID: 2668915)
1. Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate.
el-Yazigi A; Amer M; Martin CR
Pharm Res; 1989 Jun; 6(6):492-6. PubMed ID: 2668915
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of carboplatin.
Oguri S; Sakakibara T; Mase H; Shimizu T; Ishikawa K; Kimura K; Smyth RD
J Clin Pharmacol; 1988 Mar; 28(3):208-15. PubMed ID: 3283185
[TBL] [Abstract][Full Text] [Related]
3. The disposition of carboplatin in ovarian cancer patients.
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of carboplatin after intraperitoneal administration.
Elferink F; van der Vijgh WJ; Klein I; ten Bokkel Huinink WW; Dubbelman R; McVie JG
Cancer Chemother Pharmacol; 1988; 21(1):57-60. PubMed ID: 3277734
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
6. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.
Newell DR; Siddik ZH; Gumbrell LA; Boxall FE; Gore ME; Smith IE; Calvert AH
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1399-405. PubMed ID: 3315699
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
9. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
11. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
Ota K; Oguma T; Shimamura K
Anticancer Res; 1994; 14(3B):1383-7. PubMed ID: 8067710
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer.
Madden T; Sunderland M; Santana VM; Rodman JH
Clin Pharmacol Ther; 1992 Jun; 51(6):701-7. PubMed ID: 1611808
[TBL] [Abstract][Full Text] [Related]
14. Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.
Trump DL; Grem JL; Tutsch KD; Willson JK; Simon KJ; Alberti D; Storer B; Tormey DC
J Clin Oncol; 1987 Aug; 5(8):1281-9. PubMed ID: 3040920
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of carboplatin after i.v. administration.
Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
[TBL] [Abstract][Full Text] [Related]
17. The disposition of carboplatin in the beagle dog.
Gaver RC; George AM; Duncan GF; Morris AD; Deeb G; Faulkner HC; Farmen RH
Cancer Chemother Pharmacol; 1988; 21(3):197-202. PubMed ID: 3282707
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
van der Vijgh WJ; Elferink F; Vermorken JB; ten Bokkel Huinink WW; Klein I; Gall HE; Simonetti G; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):621-7. PubMed ID: 3383966
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
